



RAYTELLIGENCE

Interim Report January – March 2021

Halmstad, Sweden 2021-05-27

January 1 – March 31 2021

- Net Sales SEK 0
- Operation profit SEK -2 212 647
- Profit after financial items SEK -2 212 647
- Earnings per share SEK -0,10
- Numbers of shares 21 907 369

Significant events during the report period (2021-01-01 – 2021-03-31)

- Raytelligence is listed on the Stuttgart Stock Exchange, Germany
- Becomes partner in the PICTA project Autumn Leaves for improved case detection in close care

Significant events after the report period

- New release of EaZense
- Raytelligence signs agreements with resellers Milcross MedTech AB and NorthMerge AB
- Raytelligence receives an initial order från Careteq, Australia who are active in-home health care and the intention is to integrate EaZense into their offering

Comments from CEO



The beginning of 2021 has really been marked by feverish activity on Raytelligence.

Sales

Great focus is on sales and we have ongoing discussions with several of the most forward-leaning municipalities within digital health Sweden. Our sales pipeline has grown 10 times as large during the quarter and we have a much better presence on the market now. Both customers, partners and competitors are now very aware of our progress.

We had already expected a number of orders from the municipalities, but unfortunately the process is more time consuming, so we also have added sales resources in real estate and industry where we received several inquiries.

An agreement with Careteq (, <https://www.careteq.com.au/>), Australia has been signed to integrate EaZense into their offering to their customers, EaZense is part of a larger procurement in Australia. Careteq has the exclusive right to sell EaZense for 36 months in Australia and New Zealand. In addition, the right to market / sell the system also in the USA.

We expect revenue with this agreement in the end of this year.

EaZense

On the development side, we have released a new interface with lots of updates in the cloud service, new services have also implemented in EaZense.

Among other things, we have added functions such as being able to detect up to five people in a room and that case detection has been further developed. Work has also begun with an offline solution for the prison service and other activities where you do not want an Internet connection system, this feature will be completed during the summer.

We are now developing a function in Eazense that makes the sensor uniquely sensitive. This will lead to us being alone market with features such as heart rate measurement and measurement of very small movements.

As we are now in full swing to develop vital parameter detection in our system, we have decided to add that functionality directly in the next generation EaZense, there are several good reasons for this.

The main reason is that we have developed EaZense in a direction that will allow it to be much more sensitive.

This means that we have a new specification of hardware and software. When we have completed this, the sensor will be ready for implementation of several new important functions, including vital parameter detection.

As this will be a new product, it will also be the one that will be certified as a medical technology product class 2 for use in clinical settings, eg hospitals

The existing EaZense will continue to be a medical technology product class 1 but will be updated from MDD to the new requirement MDR.

I look forward to a continued exciting 2021 together with our customers, partners and investors.

Klas Arvidson, VD

Comments on the financial development

January – March 2021

Sales and Results

During the period January – March 2021 the company's net sales were SEK 0.

Activated work for own account were SEK 0.

Capitalized expenses for development work during the period were SEK 1,929,000.

Profit after financial items were SEK -2,213,000.

Personnel and other external costs were SEK -2,078,000.

Depreciation of tangible assets were SEK -10,000.

Financial position and cash flow

Cash flow from operation activities during the period was negative and amounted to -1,472,000.

Cash flow from financing activities during the period were SEK 0

Cash flow from investing activities were SEK – 1,986,000.

The total cash flow during the period January-March were SEK 3,498,000.

The Company's equity as of March 31, 2020 were SEK 34,598,000.

Financing

Cash and cash equivalents at the end of the period were SEK 16,611,000.

The Company has no interest-bearing liabilities.

The following sections only in Swedish

Redovisningsprinciper

Rapporten har upprättats i enlighet med årsredovisningslagen och Bokföringsnämndens allmänna råd BFNAR 2012:1 Årsredovisning och koncernredovisning, K3. Principerna är oförändrade jämfört med föregående år.

Rapporten har inte varit föremål för granskning av bolagets revisor.

Kommande finansiella rapporter

Delårsrapport Q2 2021

27 augusti 2021

Delårsrapport Q3 2021

26 november 2021

Finansiell information, resultaträkning

	2021-01-01 -2021-03-31	2020-01-01 -2020-03-31	2020-01-01 -2020-12-31
Rörelsens intäkter			
Nettoomsättning	0	342 000	342 000
Övriga rörelseintäkter	0	12 653	12 653
Summa intäkter	0	354 653	354 653
Rörelsens kostnader			
Råvaror och förnödenheter	-117 864	-27 981	-254 995
Övriga externa kostnader	-1 583 328	-1 618 506	-6 287 888
Personalkostnader	-495 063	-1 625	-197 383
Avskrivningar av materiella och immateriella anläggningstillgångar	-10 660	-2 152	-22 810
Övriga rörelsekostnader	-5 732	-196	-42 304
Summa kostnader	-2 212 647	-1 650 460	-6 805 380
Rörelseresultat	-2 212 647	-1 295 807	-6 450 727
Finansnetto	0	-2 500	-2 923
Resultat efter finansiella poster	-2 212 647	-1 298 307	-6 453 650
Resultat före skatt	-2 212 647	-1 298 307	-6 453 650
Skatt på periodens resultat	0	0	0
PERIODENS RESULTAT	-2 212 647	-1 298 307	-6 453 650
Resultat per aktie (kr)	-0,10	-0,10	-0,29

Finansiell information, balansräkning

	2021-03-31	2020-03-31	2020-12-31
TILLGÅNGAR			
Tecknat men ej inbetalt kapital	0	0	0
Anläggningstillgångar			
Balanserade utgifter för utvecklingsarbeten	18 531 094	11 839 551	16 601 953
Materiella anläggningstillgångar	192 890	24 910	146 252
Summa anläggningstillgångar	18 723 984	11 864 461	16 748 205
Omsättningstillgångar			
Färdiga varor och handelsvaror	150 000	0	0
Fordringar hos intresseföretag	109 700	109 700	109 700
Övriga kortfristiga fordringar	705 387	608 082	832 243
Förutbetalda kostnader och upplupna intäkter	72 262	76 769	48 948
Likvida medel	16 660 994	4 285 871	20 119 163
Summa omsättningstillgångar	17 698 343	5 080 422	21 110 054
Summa tillgångar	36 422 327	16 944 883	37 858 259

	2021-03-31	2020-03-31	2020-12-31
EGET KAPITAL OCH SKULDER			
Eget kapital			
Aktiekapital	1 533 516	883 144	1 533 516
Fond för utvecklingsutgifter	18 336 131	11 644 587	16 406 990
Överkursfond	52 114 128	26 315 189	52 114 128
Balanserad förlust	-35 172 932	-22 035 730	-26 790 141
Periodens förlust	-2 212 647	-1 298 306	-6 453 650
Summa eget kapital	34 598 196	15 508 884	36 810 843
Långfristiga skulder			
Kortfristiga skulder			
Leverantörsskulder	461 499	722 939	285 664
Övriga skulder	120 960	50 040	50 040
Upplupna kostnader och förutbetalda intäkter	1 241 672	663 020	711 712
Summa kortfristiga skulder	1 824 131	1 435 999	1 047 416
Summa eget kapital och skulder	36 422 327	16 944 883	37 858 259

Finansiell information, förändring av eget kapital

	2021 jan-mars	2020 jan-mars	2020 jan-dec
Ingående eget kapital	36 810 843	16 807 191	16 807 191
Periodens resultat	-2 212 647	-1 298 307	-6 453 650
Transaktioner med ägare			
Nyemission			26 457 302
Utgående eget kapital	34 598 196	15 508 884	36 810 843

Finansiell information, kassaflödesanalys

	jan-mar 2021	jan-mar 2020	jan-dec 2020
Löpande verksamhet			
Rörelseresultat efter avskrivningar	-2 212 647	-1 295 807	-6 450 727
Återläggning avskrivningar	10 660	2 152	22 810
Andra påverkande poster t.ex. koncernbidrag	0	0	0
Finansiella inbetalningar	0	0	0
Finansiella utbetalningar	0	-2 500	-2 923
Skatt	0	0	0
Förändring rörelsekapital			
Förändring lager	-150 000	0	0
Förändring kortfristiga fordringar	103 542	72 994	-123 346
Förändring kortfristiga skulder	776 715	-994 914	-1 383 496
Kassaflöde löpande verksamhet	-1 471 730	-2 218 075	-7 937 682
Finansieringsverksamhet			
Nyemission	0	0	26 457 302
Utdelningar	0	0	0
Långfristiga skulder	0	0	0
Kassaflöde finansieringsverksamhet	0	0	26 457 302
Investeringsverksamhet			
Immateriella och materiella anläggningstillgångar	-1 986 439	-1 121 717	-6 026 119
Finansiella anläggningstillgångar	0	0	0
Kassaflöde investeringsverksamhet	-1 986 439	-1 121 717	-6 026 119
Kassaflöde	-3 458 169	-3 339 791	12 493 501
Ingående kassa	20 119 163	7 625 662	7 625 662
Utgående kassa	16 660 994	4 285 871	20 119 163

Styrelsens och verkställande direktörens försäkran

Styrelsen och verkställande direktören försäkrar att delårsrapporten ger en rättvisande bild av företaget Raytelligence AB's (publ) verksamhet, ställning och resultat per den 31 mars 2021.

Raytelligence AB (publ) 559039-7088
Halmstad 2021-05-27

Jonas Vikbladh
Styrelseordförande

Klas Arvidson
Verkställande direktör, styrelseledamot

Peter Martinson
CFO, styrelseledamot

Per-Arne Viberg
CTO, styrelseledamot

Vid frågor kontakta Klas Arvidson, VD; 070-416 98 00, klas@raytelligence.com